Fortschritt Medical Supplies · Philippines
FlexiOss Bone Regenerative Biomaterial
Officially registered with the Philippines Food and Drug Administration (Ortho: CMDR-2025-04943A | Dent: CMDR-2025-04943B). Exclusively distributed nationwide by Fortschritt Medical Supplies Inc.
Having second thoughts on material safety and reliability? The Philippines Food and Drug Administration completely vouches for our compliance.
Verify our institutional credentialsTotal Cost-of-Care Analysis
Why is FlexiOss® cheaper in the long run?
Autografts and donor allografts hide their true cost — a second surgical site, longer operating-room time, and unpredictable resorption. FlexiOss® removes the harvest site entirely and accelerates structural remodeling by 50%, shortening hospital stays and lowering post-operative revision liability.
Scroll to compare the three options
FlexiOss® Biphasic Matrix
Synthetic · Out-of-pack
One site. Predictable cost. The modern standard of care.
Traditional Allograft
Donor-Sourced
A single site — but variable sourcing and weak therapeutics.
Autograft
Patient Harvest
Two surgical sites and the highest patient burden.
[ CLINICAL EVALUATION // MATRIX_DATA_04 ]
Microstructural Stability as a Targeted Antibiotic Carrier
Unlike legacy ceramics that fragment or react violently when impregnated with local therapeutics, the patented curdlan polymer triple-helix within FlexiOss® allows secure loading of targeted antibiotics directly into its porous microstructure, serving as an intraoperative localized drug delivery system without structural degradation or chemical resistance.
Verification Index: Belcarz A., Zima A., Ginalska G. “Biphasic mode of antibacterial action of aminoglycoside antibiotics-loaded elastic hydroxyapatite-glucan composite.” International Journal of Pharmaceutics, 2013.
The Product Family
One composition. Three specialisations.
FlexiOss® Ortho
PH-FDA · Orthopedic Applications
Third-generation biomaterial with mechanical parameters similar to cancellous bone. Suitable for defects up to 7 cm in length.
Key Applications
Comminuted fractures with bone-tissue defects
Long-bone defect filling and reconstruction
Trauma surgery and emergency medicine
Bone-pocket filling for tissue regeneration
FlexiOss® Ortho
PH-FDA · Orthopedic Applications
Third-generation biomaterial with mechanical parameters similar to cancellous bone. Suitable for defects up to 7 cm in length.
Key Applications
Comminuted fractures with bone-tissue defects
Long-bone defect filling and reconstruction
Trauma surgery and emergency medicine
Bone-pocket filling for tissue regeneration
~65%
HAP Granule Porosity
β-1,3
Glucan Polymer Binder
100%
Synthetic · Animal-Free
Every FlexiOss® product shares one proven biphasic composition. Exclusively distributed in the Philippines by Fortschritt Medical Supplies Inc.
Mechanism of Action
What makes FlexiOss® different.
Six clinically validated properties that separate FlexiOss® from xenograft, allograft and first-generation synthetic substitutes.
60s
to plastic state
Surgical Moldability
After a 60-second hydration in saline or autologous blood, the rigid ceramic becomes a plastic, conformable scaffold — cut with scissors, bent to irregular margins, or milled dry for patient-specific implants. Intra-operative adaptability replaces pre-fabricated sizing, cutting operating-room time and material waste.
50%
faster healing
Accelerated Ossification
High specific surface area drives Ca²⁺ and PO₄³⁻ release at the interface, upregulating osteoblast migration. Healing falls to 28 days against the 56-day standard.
100%
synthetic
Zero Contamination Risk
The curdlan polymer is a bacterial exopolysaccharide — no prion, virus or zoonotic transmission. Its triple-helix is neutral to macrophages, with no foreign-body inflammatory response.
PRP·BMP
loadable
Antibiotic Carrier Matrix
The porous HAP-curdlan matrix absorbs aminoglycoside antibiotics (e.g. gentamicin), platelet-rich plasma or growth-factor solutions — a localized release system delivering them directly at the implant site.
Precision
dry-state milling
Anatomical Conformance
In its dry state, the composite is precisely machined or milled using standard dental or orthopedic instrumentation. These micro-milled segments preserve complete structural porosity, ionic reactivity, and surface bioactivity while adapting natively to irregular, patient-specific anatomical boundaries.
3-Year
shelf life · no cold chain
Ambient Storage, Animal-Free
A fully synthetic origin removes the ethical and logistical burden of animal-derived substitutes. FlexiOss® stores at ambient temperature — no cold chain, no special handling — simplifying procurement across the Philippines and Southeast Asia.
THE REVOLUTION IN BONE REGENERATION
Once implanted, the ~65%-porous hydroxyapatite matrix absorbs blood and body fluids — carrying the patient's own growth factors into the scaffold to stimulate and regulate bone reconstruction. Its bioactive surface bonds directly to bone.
Faster Healing
Biocompatible
Generation Biomaterial
Product Overview
TriCurean composition, mechanism of action, clinical workflow
Clinical Video — Orthopedic Trauma
Live surgical application of FlexiOss® in comminuted fracture repair
Biphasic Remodeling Pathway
Upon implantation, the curdlan polymer matrix absorbs blood and physiological fluids, forming a triple-helix scaffold that is neutral to macrophages and evokes no local inflammation. Embedded hydroxyapatite granules create a calcium- and phosphate-rich, bioactive microenvironment at the defect boundary. The composite then integrates with the surrounding bone and is gradually remodelled into natural bone tissue — eliminating the need for an implant-removal reoperation.
Bioactive Mineral Surface
The hydroxyapatite surface exchanges Ca²⁺ and PO₄³⁻ ions, promoting apatite formation and direct bonding at the bone-implant interface
Triple-Helix Scaffold
Curdlan gels into a collagen-like β-1,3-glucan conformation — non-inflammatory, form-stable and slowly resorbed
Antibiotic Carrier Matrix
High soaking capacity allows intra-operative loading with aminoglycoside antibiotics (e.g. gentamicin) and other sterile solutions, released in a biphasic, pore-dependent pattern (Belcarz 2013)
Documented Bone Formation
Clinical histology shows new collagen fibres, Haversian canals and lamellar bone at the implantation site
AWARDS & RECOGNITION
MEDICAL INVENTI
Top Biomaterials Processing Company
Europe 2024 • Life Sciences Review
"FLEXIOSS WAS SUPPOSED TO LAUNCH QUIETLY... LOOKS LIKE INNOVATION NEVER STAYS SILENT!"
The Material, In Motion
Form. Integrity. Microstructure.
Optimized Geometric Variety
Surgical boundaries vary. To eliminate intraoperative modification and structural waste, FlexiOss is distributed across a full matrix of linear dimensions — from precision micro-discs engineered for dental envelopes to long structural cylinders built for segmental long-bone voids.
Integrity Under Manipulation
Legacy substitutes fracture under handling. FlexiOss holds its form through its specialized composition: gripped firmly with forceps or shaped at demanding angles, the material keeps structural cohesion — placing cleanly into the most complex defect zones.
Macroporous System Kinetics
True regeneration needs a scaffold that hosts native cellular machinery. The horizontal macro-architecture of FlexiOss carries a hyper-precise network of interconnected pores — enabling swift vascularization, uniform fluid distribution and stable localized antibiotic integration.
PUBLISHED RESEARCH
Peer-reviewed scientific publications validating FlexiOss® efficacy and safety
Characteristics and application of FlexiOss® bone substitute material in trauma-orthopedic patients
Lukasiewicz P.
Preliminary Results of Surgical Treatment for Enchondroma Using a Novel Bioactive and Osseoconductive HAP/β-Glucan Bone Substitute FlexiOss® — Case Series
Kotrych D., Ciechanowicz D., Bielewicz F., Baryluk A., Podsiadlo S., Zietek P.
Behavior of new hydroxyapatite/glucan composite in human serum
Borkowski L., Lubek T., Jojczuk M., Nogalski A., Belcarz A., Palka K., Hajnos M., Ginalska G.
The comparison study of bioactivity between composites containing synthetic non-substituted and carbonate-substituted hydroxyapatite
Borkowski L., Sroka-Bartnicka A., et al.
Biphasic mode of antibacterial action of aminoglycoside antibiotics-loaded elastic hydroxyapatite-glucan composite
Belcarz A., Zima A., Ginalska G.
Application of β-1,3-glucan in production of ceramics-based elastic composite for bone repair
Belcarz A., Ginalska G., Pycka T., et al.
